The Portfolio

Diagnostics products, matched to need and a path to reimbursement.

Four products across urinalysis, infectious disease, neurology, and oncology — each designed around real assay coverage, customer demand, and a clear commercialization route.

01 · Urinalysis Platform

MU500™ — best value in the mid-market

A cloud-connected urinalysis analyzer that delivers central-lab quality at a point-of-care footprint. Priced below premium brands while significantly outperforming low-cost alternatives in quality and compliance — built on a razor-blade model where low-friction placement drives high-margin recurring reagent revenue.

  • Full cloud QC / LIS connectivity and open HL7 / FHIR integration
  • AI image processing for sediment analysis
  • Reagent-lease option — zero capex for the customer
  • Lead time under 4 weeks vs. 8+ weeks for incumbents
<60sResult time
~88%Reagent attachment
0.5 mBench footprint
MU500™

Cloud-native urinalysis for POL labs, hospital labs, and CLIA-waived sites.

Cloud QCHL7 / FHIRAI imagingRazor-blade model
NexFlex

A single modular panel covering six pathogen ID + AMR applications.

99-mix librarySingle internal controlAI-designed4-plex per mix

02 · Pathogen ID + Antimicrobial Resistance

NexFlex — AI-designed for 100% of core customer need

Eunobio analyzed 117 customer product requirements and 340 targets, then ran five rounds of AI-assisted design plus manual refinement to converge on a single, highly reusable panel. One internal control per panel maximizes tube efficiency; a 99-mix modular library makes the menu configurable with minimal customization.

  • Single panel, single internal control — maximizing tube efficiency
  • 99-mix modular library, each mix 4-plex
  • Covers 6 pathogen ID + AMR applications
  • Built to customer requirements via a configurable, highly reusable menu
237Targets covered
99Modular mixes
100%Core need coverage

03 · Neurology · Alzheimer's

Whole-blood Alzheimer's test — central-lab standards at the frontline

A whole-blood electrochemiluminescence analyzer that brings central-lab-grade accuracy to the clinical frontline. Methodology aligned with central-lab standards and highly concordant with Roche, it loads whole blood directly — no centrifugation, no pre-processing — so a sample stays put and the report is ready instantly.

  • p-tau217 and multi-marker combined testing (Aβ42/Aβ40, NfL/GFAP)
  • Whole blood loaded directly — no centrifugation pre-processing
  • Compact 0.5 m instrument for outpatient, inpatient, and primary care
  • Aligned with the ≤20-minute chest-pain-center turnaround requirement
12 minWhole-blood TAT
7 minSerum TAT
CV <3%Precision
12 min

Whole-blood electrochemiluminescence — no centrifugation, central-lab concordance.

p-tau217Multi-markerCV <3%0.5 m footprint
NGS

An oncology NGS panel where the moat is the reimbursement pathway, not the sequencing.

PLA codesLCD dossiersCMS Z-codePayer engagement

04 · Oncology NGS

Oncology NGS — cracking reimbursement is the real moat

For NGS, the bottleneck isn't sequencing technology — it's coverage. Once a payer issues a PLA code and coverage policy, single-site orders can jump from zero to tens of thousands a year. Eunobio's Payer-Evidence AI pipelines the whole pathway: evidence dossiers, code & pricing, and payer engagement, running case-by-case coverage automatically.

  • Evidence AI — auto-generates clinical + health-economic dossiers (80+ pages)
  • Code & Pricing — PLA, Z-code, and crosswalk recommendations from CMS monitoring
  • Payer Engagement — P&T templates and KOL letters across 200+ commercial payers
  • Four payer tracks in parallel — Medicare, commercial, Medicaid, and CDx
12–18 moCoverage pathway
vs 24–36 moIndustry average
4-trackPayer strategy

Partner with us

Have a diagnostics product to bring to the US?

We onboard products around real customer need and a clear reimbursement pathway — then commercialize them with the AI Sales OS.

sales@eunobio.com See the Platform